ABSTRACT
Treatment of hereditary breast cancer, as that of all types of breast cancer, can be broadly
divided into local and systemic phases. In a preceding chapter, the influence of germline
predisposition on local management decisions, particularly the appropriateness of breast
conserving treatment, is considered. In this chapter, we will consider the question of
whether women with hereditary breast cancer should be approached differently when it
comes to decision-making about systemic adjuvant therapy.
